ZANAVIR CA atazanavir 150 mg capsule bottle pack

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

atazanavir sulfate, Quantity: 170.85 mg (Equivalent: atazanavir, Qty 150 mg)

Verfügbar ab:

Cipla Australia Pty Ltd

INN (Internationale Bezeichnung):

Atazanavir sulfate

Darreichungsform:

Capsule, hard

Zusammensetzung:

Excipient Ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; Gelatin; sodium lauryl sulfate

Verabreichungsweg:

Oral

Einheiten im Paket:

30 capsules, 60 capsules

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

Atazanavir is indicated for the treatment of HIV 1 infection, in combination with other antiretroviral agents. This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts from controlled studies (See Clinical Trials).

Produktbesonderheiten:

Visual Identification: White to pale yellow granules filled in size 1 hard gelatin capsule with maroon cap & white body spin printed with Cipla 150 on cap with white ink.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Berechtigungsstatus:

Licence status A

Berechtigungsdatum:

2017-08-30